Alerta

LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF

Absstract of: AU2024359608A1

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

Peptide for the delivery of anionic materials

Absstract of: GB2644439A

The invention provides a peptide or a salt or amide thereof, for use as a cell delivery agent, comprising, or consisting of: (Xaa1)a-(Xaa2)b-LYRLFRKS-(Xaa3)c-(Xaa4)d-(Xaa4)e-NLKPFERHARAC, wherein: a, b, and c can be either 0 or 1; d and e are 1; Xaa1-2 represent Ala, Val or Gly; and Xaa3-5 represent His or Trp. An exemplary sequence, AALYRLFRKSWHNLKPERHARAC, when combined with mRNA, forms 103 nm nanoparticles with a charge of 19 mV and polydispersity index of 0.06, and can transfect NCTC-929 cells with an efficiency of up to 81%. The particles are also shown to encapsulate miRNA and plasmid DNA with an encapsulation efficiency up to 95%. Also claimed is the first medical use of the peptide in gene therapy, and second medical use of the peptide in the treatment of prophylaxis, infection, cancer and wounds.

Veterinary compositions

Absstract of: GB2644423A

The invention relates to sterile veterinary formulations for treating or preventing mastitis in cattle. The formulations comprise a suspension of Derivatised Microparticles, optionally in combination with Microparticles, in an amount of 5 percent to 60% w/v. The Derivatised Microparticles and Microparticles are biodegradable and are formed from an organic polycationic polymer and a saturated or unsaturated fatty dicarboxylic acid. Suitable polymers may include organic polymeric amines, quaternary ammonium compounds, polypeptides and carbohydrates, with preferred antimicrobial polymers such as nisin, ε‑polylysine or chitosan. In preferred embodiments, the microparticles are formed from sebacic acid and ε‑polylysine and the fatty dicarboxylic acid to polymer molar ratio is around 1:1. The suspension may comprise 20 % to 50 % microparticles, preferably around 30 %, in a veterinary acceptable carrier such as water, mineral oil, liquid paraffin or white soft paraffin. The microparticles may be present as a mixture, with the ratio of Derivatised Microparticles to Microparticles ranging from 90:10 to 10:90. The formulation may be administered during the dry period of the cow and provides an effective method for treating or preventing mastitis. The invention further includes mixtures of Derivatised Microparticles and Microparticles and veterinary formulations containing such mixtures.

POLYMERIC PRODRUG NANOPARTICLE FOR TUMOR-TARGETED ULTRASOUND-ACTIVATED CANCER THERAPY

Absstract of: EP4725504A1

A polymeric prodrug nanoparticle for the targeted accumulation and activation in tumor tissue, consisting of the following monomers:a) at least one platinum(IV) complex andb) at least one sonosensitizer, andc) a compound having a hydrophilic group providing this hydrophilic group at each terminal end of the prodrug nanoparticle, wherein a), b) and c) are each covalently bonded to one another by means of a linker and a) and b) are arranged stochastically distributed within the polymeric prodrug nanoparticle can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. Upon irradiation of the polymeric prodrug nanoparticle with ultrasound, the platinum(IV) prodrug is activated in the tumor region, resulting in the release of cytotoxic platinum and killing of tumor cells.

TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS WITH AROMATIC HEAD GROUPS

Absstract of: WO2024256457A1

The present invention provides, in part, tricene and citric acid-based cationic lipids with aromatic head groups of Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

A NANOPARTICLE COMPOSITION AND RELATED METHODS THEREOF

Absstract of: WO2024253582A1

There is provided a nanoparticle composition comprising a compound represented by general formula (1) or ionized form thereof, wherein R1, R2, and R4 to R8 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene, and R9 and R10 are each independently a hydrophobic tail or contains at least one of the groups defined above for R4 to R8; a therapeutic, prophylactic, and/or biological agent that is encapsulated by the compound of general formula (1) to form nanoparticles; and a cryoprotectant. There is also provided a method of preparing said nanoparticle composition.

IONIZABLE LIPID COMPOUND, LIPID CARRIER COMPRISING SAME AND USE THEREOF

Absstract of: EP4725938A1

The present invention relates to an ionizable lipid compound, a lipid carrier comprising same and the use thereof. Provided in the present invention are a series of compounds as represented by formula (1), a lipid carrier comprising same as an ionizable lipid, a nucleic acid lipid nanoparticle composition and a preparation thereof. A lipid nanoparticle formed from the ionizable lipid can deliver a nucleic acid molecule into the body, so that the transfer rate of a nucleic acid molecule is increased, and the treatment effect of a nucleic acid drug is improved.

LIPID-POLYMER HYBRID NANOPARTICLES

Absstract of: WO2024252406A1

Present disclosure describes a lipid polymer hybrid nanoparticle and a method to synthesize such nanoparticles or such nanoparticle-containing compositions. The nanoparticles are made of biodegradable polymer based micellar core surrounded by lipid-based shell, wherein majority of a pharmaceutical agent is present on the inner periphery of such nanoparticles due to physical adherence with the lipid molecules. Only a minor amount of the pharmaceutical agent is encapsulated in the micellar core. Hence, the lipid-based shell becomes a primary excipient part of the nanoparticle and the biodegradable polymer containing core becomes a secondary excipient part of the nanoparticle.

SUBMICRON PARTICLE COMPRISING A PEPTIDE ACTIVE, PREPARATION METHOD AND USES THEREOF, IN PARTICULAR COSMETIC USES

Absstract of: FR3149503A1

La particule submicronique est sensiblement sphérique comprenant un cœur huileux renfermant l’actif peptidique et une enveloppe de cire solide à température ambiante. La particule est stabilisée par une couche extérieure d’un tensio-actif non-ionique à haut HLB. L’invention propose un procédé pour obtenir une suspension aqueuse desdites particules présentant un taux d’encapsulation satisfaisant et une stabilité à long terme améliorée, pour une utilisation notamment dans l’industrie des cosmétiques. Des combinaisons de peptides sont possibles intégrées à l’intérieur des particules et adsorbés à l’extérieur. Fig. 1

EFFICIENT CATIONIC POLYESTER AND USE THEREOF

Absstract of: EP4725977A1

Disclosed in the present invention are an efficient cationic polyester and the use thereof. The cationic polyester of the present invention is a hyperbranched polymer formed by means of polymerizing three monomers of monomer P, monomer S and monomer M, or two monomers of monomer P and monomer S, with monomer T. The hyperbranched polymer has an end group modified with group E, and the group E has a relative concentration of 0.48-0.75 to group E of a hyperbranched polymer with complete end-group modification. Monomer P is cyclic lactone. Monomer S is an organic acid with an end group containing two or more carboxyl. Monomer M is a compound containing two hydroxyl and one secondary amine or tertiary amine. Monomer T is a compound containing at least three hydroxyl. The end-group modifying compound E which provides group E modification is a compound containing at least one primary amine, secondary amine or tertiary amine group. The cationic polyester of the present invention only has a part of the end groups modified with group E, has higher nucleic acid transfection efficiency when being used for nucleic acid drug delivery, has low cytotoxicity, and can be used in clinical practice.

BACKPACKED-ANTIBODY CONSTRUCTS AND THEIR USES

Absstract of: WO2024251979A1

The present invention is comprised within the fields of molecular biology and biotechnology. It specifically relates to polypeptides for the generation of Backpacked-antibody (B-ab) molecules for a variety of uses, in particular, for the specific delivery of drugs to tumor cells.

EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE

Absstract of: EP4726038A1

This application relates to an engineered RNA molecule, a DNA molecule encoding the engineered RNA molecule, and use of the engineered RNA molecule. The engineered RNA molecule comprises a Poly(A) tail sequence containing an miRNA binding site. The Poly(A) tail enables the accurate expression of a target gene in an organ, a tissue and/or a cell.

RNA-LOADED LIPID NANOPARTICLES

Absstract of: WO2024253741A1

Compositions are provided that include a lipid nanoparticle (LNP);a self-replicating RNA encoding a gene of interest loaded within the LNP; and an inhibitory nucleic acid, such as a small interfering RNA (siRNA) targeting IFN-α/β receptor l(Ifharl) gene loaded within the LNP, and use of the compositions for generating an immune response.

CD177靶向膜修饰脂质体在制备预防和/或治疗系统性红斑狼疮的药物中的应用

Absstract of: CN121846047A

本发明公开了CD177靶向膜修饰脂质体在制备预防和/或治疗系统性红斑狼疮的药物中的应用。所述CD177靶向膜修饰脂质体，其结构分为三层，包括：负载PADI4抑制剂的脂质体、在所述脂质体的表面偶联CD177靶向肽形成的靶向识别层、以及最外层包覆天然中性粒细胞膜形成的仿生功能层。在咪喹莫特（IMQ）诱导的狼疮模型中，所述药物治疗显示出强大的疾病缓解能力：1）改善全身表型：显著缩小狼疮小鼠肿大的脾脏和淋巴结。2）修复肾脏功能：显著缓解肾小球肾炎，减少肾小球内炎性细胞浸润、IgG及补体C3沉积。3）显著降低血清中促炎细胞因子水平及狼疮标志物抗dsDNA抗体的滴度。

一种肉桂醛纳米颗粒的制备方法及其应用

Absstract of: CN121846049A

本发明公开了一种肉桂醛纳米颗粒制备方法及其应用，制备方法以肉桂醛为功效成分，玉米醇溶蛋白为载体，酪蛋白酸钠为稳定剂，果胶为稳定剂和粘合剂，制备获得所述肉桂醛纳米颗粒。经试验验证，本发明制备的肉桂醛纳米颗粒能显著提高肉桂醛的稳定性，同时增强其对于金黄色葡萄球菌的抗菌活性，为肉桂醛的开发利用提供了更多选择。

一种修饰可电离胺基的双介孔二氧化硅纳米颗粒及其制备方法和应用

Absstract of: CN121846313A

本发明公开了一种修饰可电离胺基的双介孔二氧化硅纳米颗粒及其制备方法和应用，其核心技术流程包括：首先通过嵌段共聚物与表面活性剂的双模板法合成介孔二氧化硅；然后将可电离胺基通过硅烷偶联剂接枝到介孔二氧化硅表面；最后利用静电吸附将RNA负载到修饰后的介孔二氧化硅上，最终实现肿瘤高效治疗。本发明还公开一种上述二氧化硅纳米颗粒在RNA递送中的应用，根据本发明方法制备的二氧化硅纳米颗粒有着高效的RNA负载效率以及细胞摄取效率。根据本发明制备的修饰可电离氨基团的双介孔二氧化硅纳米颗粒具有药物负载量大、细胞摄取率高、生物相容性高、合成简单、反应条件温和、便于裁剪等优点，具有良好的应用前景。

一种莲源多糖靶向纳米载药系统及其应用

Absstract of: CN121846300A

本发明公开了一种莲源多糖靶向纳米载药系统及其应用，由活性成分和包裹所述活性成分的载体材料组成；所述活性成分为莲藕多糖LSP‑1，所述LSP‑1是从莲藕中提取纯化的均一多糖，分子量为3.2×10⁴Da，其单糖组成为葡萄糖、半乳糖和阿拉伯糖，摩尔比为5.2:2.8:1.0；所述载体材料为两亲性聚合物，以聚β‑氨基酯为主链，主链中引入二硫键，聚合物末端修饰有穿膜肽TAT和聚乙二醇；本发明首次提出并验证了“汇聚式协同”免疫调控新机制。本发明观察到的“汇聚式协同”效应是特定于“LSP‑1”与“本发明的PBAE基响应型载体”这一组合的，二者在机制上存在特定的生化信号通路交互，并非任何免疫调节剂与任何纳米载体的简单叠加所能实现。

一种基于聚乙烯吡咯烷酮修饰的硒纳米粒子的制备方法及其应用

Absstract of: CN121849857A

本发明提供了一种基于聚乙烯吡咯烷酮修饰的硒纳米粒子的制备方法，包括以下步骤：S1、还原反应：在惰性气体保护下，将硒源与硼氢化钠在水溶液中于室温下进行还原反应，生成硒氢化钠中间体；S2、稳定化反应：向步骤S1所得的反应体系中加入聚乙烯吡咯烷酮水溶液，继续在惰性气体保护下进行稳定化反应，使聚乙烯吡咯烷酮修饰在生成的硒纳米粒子表面；S3、纯化与收集：将步骤S2所得的反应液进行纯化，去除小分子杂质，然后进行冻干，即得到基于聚乙烯吡咯烷酮修饰的硒纳米粒子固体粉末。本发明提供的基于聚乙烯吡咯烷酮修饰的硒纳米粒子的制备方法，具有原料更安全、工艺更简洁、产物更纯净等优点。

纳米载体Ir-Mn-CMP NPs的制备及其生物医学应用

Absstract of: CN121846273A

本发明公开了一种纳米载体Ir‑Mn‑CMP NPs的制备及其生物医学应用。所述纳米载体Ir‑Mn‑CMP NPs通过利用声敏剂铱（III）配合物【Iridium(III) complex，Ir(III)】、锰（Mn）和环状GMP‑AMP（cGAMP）的组合，联合声动力治疗与STING（stimulator of interferon genes）通路激活免疫治疗，提升抗肿瘤治疗效果。此设计不仅能够增强声敏剂的稳定性和水溶性，还能够提高Mn的肿瘤靶向性和生物利用度，同时实现声动力治疗和STING通路免疫激活的双重治疗效果。

一种巨噬细胞仿生囊泡纳米制剂及其制备方法和应用

Absstract of: CN121846128A

本发明属于生物医药技术领域，具体涉及一种巨噬细胞仿生囊泡纳米制剂及其制备方法和应用。本发明提供了一种巨噬细胞仿生囊泡纳米制剂，使用肿瘤靶向肽对巨噬细胞仿生囊泡进行修饰，并包裹靶向NSUN家族甲基转移酶siRNA。经肿瘤靶向肽修饰后的巨噬细胞仿生囊泡具有良好的胃癌细胞靶向性，包裹靶向NSUN家族甲基转移酶siRNA可抑制胃癌细胞NSUN表达水平、降低胃癌m5C异常修饰水平，达到增强PD‑1抗体治疗胃癌效果。实施例结果表明，本发明提供的巨噬细胞仿生囊泡纳米制剂作用于胃癌细胞，能够特异性靶向胃癌细胞，诱导胃癌细胞铁死亡，提高PD‑1抗体疗效，延长小鼠生存时间，改善肿瘤免疫微环境。

RSV疫苗

Absstract of: WO2025017142A1

Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a stabilised prefusion RSV F protein immunogen linked to a scaffold based on lumazine synthase.

一种黄芪甲苷协同型组合物及其制备方法与应用

Absstract of: CN121846175A

本发明公开了一种黄芪甲苷协同型组合物及其制备方法与应用，黄芪甲苷协同型组合物其原料按重量份数计，包括如下组分：黄芪甲苷8‑16份、金银花提取物20‑40份、左旋肉碱10‑20份、酵母硒0.1‑0.5份、甘草酸二铵3‑8份、牛磺酸5‑15份、连翘提取物8‑20份、维生素E2‑7份、羟丙基‑β‑环糊精12‑32份、麦芽糊精2‑10.5份、阿拉伯胶1‑7份、乳糖10‑20份、葡萄糖酸锌1‑3份、硬脂酸镁2‑5份、维生素C 1‑3份、黄原胶1‑5份和卵磷脂1‑3份。该组合物在在制备兽药或兽用食品添加剂中具有广泛的应用前景。

一种基于酰化多糖和小檗碱的复合载药纳米粒及制备方法和应用

Absstract of: CN121846048A

本申请涉及纳米医药载体技术领域，尤其涉及一种基于酰化多糖和小檗碱的复合载药纳米粒及制备方法和应用。所述制备方法包括：使用碱性催化剂和酸酐将天然多糖进行酰化改性，得到酰化天然多糖；其中，所述酰化改性的方式包括乙酰化改性或者丙酰化改性；在有机溶剂中，将小檗碱和酰化天然多糖进行包封处理，得到基于酰化多糖和小檗碱的复合载药纳米粒。该制备方法通过对天然多糖进行酰化改性，调整天然多糖的疏水性，实现小檗碱包封率的显著提升。一方面，该复合载药纳米粒可以显著提升小檗碱的生物利用度，并延长小檗碱在体内的作用时间，另一方面，该复合载药纳米粒可以促进金黄色葡萄球菌感染的伤口的修复愈合，降低金黄色葡萄球菌的耐药性。

枳实细胞外囊泡样颗粒及其制备方法与应用

Absstract of: CN121852306A

本发明属于中药技术领域，公开了枳实来源的细胞外囊泡样纳米颗粒，其特征在于，所述枳实来源的细胞外囊泡样纳米颗粒通过将枳实进行破碎、过滤、离心、重悬的步骤制备得到，平均粒径为60~120 nm，该细胞外囊泡样纳米颗粒包载柚皮苷、新橙皮苷、柚皮素和橙皮苷中的至少一种。本发明的枳实来源的细胞外囊泡样纳米颗粒制备方法简单，具有肝脏靶向性和良好的稳定性，可用于制备预防和/或治疗肝损伤、抑郁症与乳腺癌的药物。

一种MXene@Au光热纳米马达及其制备方法和应用

Nº publicación: CN121846277A 14/04/2026

Applicant:

暨南大学

Absstract of: CN121846277A

本发明属于纳米马达技术领域，具体涉及一种MXene@Au光热纳米马达及其制备方法和应用。本发明提供的MXene@Au复合纳米马达，包括改性单层MXene纳米片以及负载于改性单层MXene纳米片表面的活性组分；所述活性组分为牛血清白蛋白包覆的金纳米簇；所述改性单层MXene纳米片经阳离子表面活性剂改性得到；所述负载通过静电吸附作用实现。本发明提供的MXene@Au纳米马达在光照下产生非对称热梯度，驱动纳米马达在溶液中实现自推进运动，可显著增强在复杂生物介质中的扩散效率与Aβ靶向富集能力，进而实现对Aβ蛋白聚集体的高效识别与光热降解。